This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Pardes Biosciences Gestion
Gestion contrôle des critères 1/4
Pardes Biosciences' CEO is Tom Wiggans, appointed in Mar 2022, has a tenure of 1.5 years. total yearly compensation is $5.26M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.082% of the company’s shares, worth $107.99K. The average tenure of the management team and the board of directors is 2.7 years and 2.4 years respectively.
Informations clés
Tom Wiggans
Directeur général
US$5.3m
Rémunération totale
| Pourcentage du salaire du PDG | 9.9% |
| Durée du mandat du directeur général | 1.5yrs |
| Propriété du PDG | 0.08% |
| Durée moyenne d'occupation des postes de direction | 2.7yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.4yrs |
Mises à jour récentes de la gestion
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$76m |
| Mar 31 2023 | n/a | n/a | -US$93m |
| Dec 31 2022 | US$5m | US$521k | -US$97m |
Rémunération vs marché: Tom's total compensation ($USD5.26M) is above average for companies of similar size in the US market ($USD758.93K).
Rémunération et revenus: Insufficient data to compare Tom's compensation with company performance.
PDG
Tom Wiggans (71 yo)
1.5yrs
Titularisation
US$5,255,958
Compensation
Mr. Thomas G. Wiggans, also known as Tom, serves as Independent Director at CymaBay Therapeutics, Inc. since April 2021. He serves as an Executive Chairman of Follica, Inc. since January 2021. He serves as...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.5yrs | US$5.26m | 0.082% $ 108.0k | |
| Founder & Director | no data | US$3.52m | 9.35% $ 12.3m | |
| Chief Financial Officer | 2.7yrs | US$1.82m | 0.52% $ 684.2k | |
| General Counsel & Corporate Secretary | 2.7yrs | pas de données | 0.35% $ 456.1k |
2.7yrs
Durée moyenne de l'emploi
56.5yo
Âge moyen
Gestion expérimentée: PRDS's management team is considered experienced (2.7 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.5yrs | US$5.26m | 0.082% $ 108.0k | |
| Founder & Director | 3.6yrs | US$3.52m | 9.35% $ 12.3m | |
| Director | 2.7yrs | US$110.69k | pas de données | |
| Independent Director | 2.7yrs | US$170.69k | 0.12% $ 152.0k | |
| Independent Director & Member of Scientific Advisory Board | 3.1yrs | US$153.69k | 0.12% $ 152.0k | |
| Independent Director | 2.7yrs | US$163.19k | 2.25% $ 2.9m | |
| Independent Director | less than a year | US$147.00k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$161.19k | 0% $ 0 | |
| Lead Independent Director | less than a year | US$146.94k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$153.69k | 0% $ 0 | |
| Member of Commercial Advisory Board | no data | pas de données | pas de données |
2.4yrs
Durée moyenne de l'emploi
62.5yo
Âge moyen
Conseil d'administration expérimenté: PRDS's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.